Please select a Capability in order to start your service request.
SAN JOSE, CA., Nov. 12 2015 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received Frost & Sullivan’s 2015 Global Company of the Year Award for Clinical and Research Flow Cytometry.
Frost & Sullivan analysts independently evaluate candidates for the Global Company of the Year Award based on three key factors: visionary innovation, performance and customer impact. BD was recognized for its large and diverse customer base, broad product portfolio, consistent track record of reliability and supply chain excellence, and quality customer service among other factors.
"BD offers robust products that incorporate innovative hardware, software, multiple reagents (including a broad portfolio of bright fluorescent dyes), an automated setup and stringent quality control," said Divyaa Ravishankar, team leader - senior industry analyst and associate fellow at Frost & Sullivan. "In addition to being first to market, BD has established clear credibility for its products among end users.";
BD’s principal Biosciences product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media and supplements for biopharmaceutical manufacturing.
"We are honored to be recognized by Frost & Sullivan," said Claude Dartiguelongue, worldwide president of Biosciences for BD. "For more than 40 years, BD has partnered with our global research and clinical customers to expand knowledge of the single cell. Today, these discoveries and applications help to improve the diagnosis and understanding of many different diseases impacting the world."
For more information on the Frost & Sullivan Global Company of the Year Award, please visit ww2.frost.com.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.